NeuroBo Q3 2023 net loss $3.8M; cash $25.8M; DA-1241 Phase 2a first patient dosed

MetaVia Inc.

2023-Q3 EPS reported -$0.18

Net loss $3.8M in Q3 2023 (EPS -$0.09) compared to net loss $3.1M (EPS -$3.50) in Q3 2022.
Cash and cash equivalents $25.8M as of Sep 30, 2023; expected to fund operations into Q4 2024.
First patient dosed in Phase 2a trial of DA-1241 for NASH; interim data expected H1 2024, full data H2 2024.
DA-1726 IND submission for obesity expected by year-end 2023; Phase 1a initiation targeted H1 2024.
Appointed James P. Tursi, M.D. to Board of Directors in November 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

MetaVia Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, NeuroBo Pharmaceuticals, Inc. (the “Company” ) issued a press release announcing its financial results for the third quarter ended September 30, 2023 and providing a corporate update.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018835

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.